Table 2.

Efficacy by Central Radiographic Assessment.

All patients N = 339DLL3-high N = 238DLL3-positive N = 287
Primary endpoints
 Objective response rate, n (%)42 (12.4)34 (14.3)38 (13.2)
 (95% CI)(9.1–16.4)(10.1–19.4)(9.5–17.7)
 Overall survival, median (mo)5.65.75.8
 (95% CI)(4.9–6.1)(4.9–6.7)(5.1–6.7)
Secondary endpoints
 Duration of objective response, median (mo)4.03.73.7
 (95% CI)(3.0–4.2)(2.9–4.2)(2.9–4.2)
 Progression-free survival, median (mo)3.53.83.8
 (95% CI)(3.0–3.9)(3.2–4.1)(3.2–4.0)
 Disease control rate, n (%)236 (69.6)175 (73.5)206 (71.8)
 (95% CI)(64.4–74.5)(67.4–79.0)(66.2–76.9)
  • Abbreviations: DLL3, delta-like 3 protein; CI, confidence interval; mo, months.